CoChat

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 10 of the 16 sources its claims cite were checked for support.

Abstract

Even though highly active anti-retroviral therapy is able to keep HIV-1 replication under control, the virus can lie in a dormant state within the host genome, known as a latent reservoir, and poses a threat to re-emerge at any time. However, novel technologies aimed at disrupting HIV-1 provirus may be capable of eradicating viral genomes from infected individuals. In this study, we showed the potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression. When LTR-targeting CRISPR/Cas9 components were transfected into HIV-1 LTR expression-dormant and -inducible T cells, a significant loss of LTR-driven expression was observed after stimulation. Sequence analysis confirmed that this CRISPR/Cas9 system efficiently cleaved and mutated LTR target sites. More importantly, this system was also able to remove internal viral genes from the host cell chromosome. Our results suggest that the CRISPR/Cas9 system may be a useful tool for curing HIV-1 infection.

Overview

CoChat Summary

TL;DR

The study shows that CRISPR/Cas9 targeting the HIV-1 LTR can disrupt proviral expression and excise integrated provirus in cell models. T5 gRNA targeting the TAR region was more effective than T6 targeting NF-κB, and repeated transfection improved suppression and excision.

Key findings

  • In LTIG-transduced 293T cells, T5 gRNA reduced GFP-positive cells from 45.6% to 20.0% (p = 0.0003); triple transfection reduced GFP-positive cells from 40.8% to 2.1% (p = 0.0001).
  • Sequence analysis found mutations in 18 of 22 HIV DNA clones, with 1–31-bp deletions from the putative cleavage site; two clones had deletion plus insertion mutations, consistent with NHEJ repair.
  • In latent Jurkat clones c5 and c19, T5 reduced TNF-α-induced GFP-positive cells from 92.56% to 68.78% and from 98.48% to 66.95%, respectively; after three transfections in c19, reactivation fell from 97.8% to 35.5% (p = 0.00002).
  • qPCR showed that on average 31.8% of provirus was excised after three transfections, and PCR detected a 1,067-bp footprint consistent with provirus excision leaving one LTR.

Methods

  • Designed gRNA expression vectors targeting HIV-1 LTR: T5 against the TAR sequence in the R region and T6 against the NF-κB binding sequence in U3, co-transfected with human codon-optimized Cas9.
  • Used HIV-1 provirus-integrated human cells: LTIG vector-transduced 293T and HeLa cells, plus Jurkat clones c5 and c19 that mimic HIV latency and were reactivated with TNF-α or 5-Aza-dC/TSA.
  • Assessed GFP expression by flow cytometry, mutations by cloning and sequencing, proviral DNA amount by qPCR, and integration/excision by inverse PCR and flanking PCR; statistical analysis used Student’s t test.

Limitations

  • The paper states that genome-editing and/or proviral excision efficiency should be quantified in HIV-infected primary cells, including latently infected CD4+ quiescent T cells.
  • The paper states that an efficient delivery system must be developed and that possible off-target effects remain a concern for all genome-editing strategies.
  • Evident from the text: most experiments use cell lines and engineered HIV vectors rather than primary patient cells; HeLa responses were modest, attributed to lower transfection efficiency and lower GFP expression; T6 was weaker because the 3′ NF-κB site may remain functional; and target-site mutations could allow some provirus to escape editing.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/srep02510

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Suppression of HIV-1 gene expression by the CRISPR/Cas9 system targeting HIV-1 LTR. (A) Schematic of provirus derived from LTIG vector and the LTR. Two target sites of CRISPR/Cas9 were indicated at the bottom of the LTR. (B and C) GFP expression after CRISPR/Cas9 treatment. 293 T and HeLa cells were infected with LTIG vector pseudotyped with VSV-G protein. One week after infection, the cells were co-transfected with gRNA expression vector and hCas9 expression vector. The level of GFP expression was analyzed by flow cytometry at 5 days after TF. (B) Representative histograms are shown. (C) GFP positive percentages (top, n = 3), and MFIs (bottom, n = 3) are shown. (D) Percentage of GFP positive 293 T cells after multiple TF with the CRISPR/Cas9 system. Flowchart of the experiment is depicted on the left side. The percentage of GFP positive cells resulting from single, double and triple TF is shown on the right side. The error bars in C and D show standard deviations (n = 3).
Figure 1 Suppression of HIV-1 gene expression by the CRISPR/Cas9 system targeting HIV-1 LTR. (A) Schematic of provirus derived from LTIG vector and the LTR. Two target sites of CRISPR/Cas9 were indicated at the bottom of the LTR. (B and C) GFP expression after CRISPR/Cas9 treatment. 293 T and HeLa cells were infected with LTIG vector pseudotyped with VSV-G protein. One week after infection, the cells were co-transfected with gRNA expression vector and hCas9 expression vector. The level of GFP expression was analyzed by flow cytometry at 5 days after TF. (B) Representative histograms are shown. (C) GFP positive percentages (top, n = 3), and MFIs (bottom, n = 3) are shown. (D) Percentage of GFP positive 293 T cells after multiple TF with the CRISPR/Cas9 system. Flowchart of the experiment is depicted on the left side. The percentage of GFP positive cells resulting from single, double and triple TF is shown on the right side. The error bars in C and D show standard deviations (n = 3).CC BY · PubMed Central
Figure 2 Sequencing analysis of the CRISPR/Cas9-target site. DNA sequence of the TAR region of LTR is indicated. Twenty-two sequences were obtained from LTIG-infected 293 T cells which were transfected three times with T5 gRNA. The WT reference sequence is shown on the top. The target sequence of T5 is indicated in orange. The putative cleavage site is indicated with an arrowhead. (A) TAR sequence with deletions. Eighteen out of 22 clones were deletion mutants. (B) TAR sequence with both deletions and insertions. Two out of 22 clones were mutants consisting of insertion and deletion. Red and blue colors indicate insertion and unanticipated mutation, respectively.
Figure 2 Sequencing analysis of the CRISPR/Cas9-target site. DNA sequence of the TAR region of LTR is indicated. Twenty-two sequences were obtained from LTIG-infected 293 T cells which were transfected three times with T5 gRNA. The WT reference sequence is shown on the top. The target sequence of T5 is indicated in orange. The putative cleavage site is indicated with an arrowhead. (A) TAR sequence with deletions. Eighteen out of 22 clones were deletion mutants. (B) TAR sequence with both deletions and insertions. Two out of 22 clones were mutants consisting of insertion and deletion. Red and blue colors indicate insertion and unanticipated mutation, respectively.CC BY · PubMed Central
Figure 3 Suppression of proviral re-activation in T cells by the CRISPR/Cas9 system. Jurkat cell lines latently-transduced with LTIG vector were used. These cell lines were co-transfected with gRNA expression vector and hCas9 expression vector. The cells were treated with TNF-α or the combination of 5-Aza-dC and TSA 4 days after TF. (A and B) The level of GFP expression after 48 hours of TNF-α stimulation and 24 hours 5-Aza-dC and TSA stimulation. Representative histograms are shown in A. The positive percentage of GFP is shown in B (n = 3). (C) Multiple TF of T5 or gRNA empty vector and hCas9 expression plasmid. Solid lines with squares and circles indicate c19 and c5 co-transfected with gRNA empty and hCas9 expression vector, respectively. Dotted lines with x and triangles indicate c19 and c5 co-transfected with T5 and hCas9 expression vector, respectively. The error bars in B and C show standard deviations (n = 3).
Figure 3 Suppression of proviral re-activation in T cells by the CRISPR/Cas9 system. Jurkat cell lines latently-transduced with LTIG vector were used. These cell lines were co-transfected with gRNA expression vector and hCas9 expression vector. The cells were treated with TNF-α or the combination of 5-Aza-dC and TSA 4 days after TF. (A and B) The level of GFP expression after 48 hours of TNF-α stimulation and 24 hours 5-Aza-dC and TSA stimulation. Representative histograms are shown in A. The positive percentage of GFP is shown in B (n = 3). (C) Multiple TF of T5 or gRNA empty vector and hCas9 expression plasmid. Solid lines with squares and circles indicate c19 and c5 co-transfected with gRNA empty and hCas9 expression vector, respectively. Dotted lines with x and triangles indicate c19 and c5 co-transfected with T5 and hCas9 expression vector, respectively. The error bars in B and C show standard deviations (n = 3).CC BY · PubMed Central
Figure 4 Excision of HIV-1 provirus from host cell genome with CRISPR/Cas9. (A) Excision of lentivirus vector with the CRISPR/Cas9 system. 293 T cells, transduced with lentivirus vector containing an EF promoter derived-EGFP expressing cassette, were treated with the CRISPR/Cas9 system. A schematic of the lentivirus vector used in this assay is shown on top. The percentage of GFP positive cells after single or double TF of CRISPR/Cas9 components is shown on the bottom (n = 3). (B) Excision of LTIG provirus with CRISPR/Cas9 system. The genomic DNA was extracted from the samples derived from Fig. 3C and qPCR was performed (n = 3). The relative amount of EGFP DNA is shown. (C) PCR amplification of HIV-1 provirus. A primer set was designed for the host cell genome sequence flanking the proviral integration site in c19. The schematic of PCR products indicating genomic sequences, full-length provirus and one LTR footprint resulting from proviral excision are shown on the right side. (D) DNA sequence of one LTR footprint resulted from proviral excision. TAR sequence of WT LTR is shown on the top in bold. Target sequence of T5 gRNA is indicated in orange. The putative cleavage site is indicated with an arrowhead. LTR sequences from five clones are shown in the middle. Deletions are indicated by dashes. Insertion is shown in Red. The 5-bp direct repeat in host DNA, flanking LTR ends, is shown in green. The host cell genome sequence is indicated on the bottom.
Figure 4 Excision of HIV-1 provirus from host cell genome with CRISPR/Cas9. (A) Excision of lentivirus vector with the CRISPR/Cas9 system. 293 T cells, transduced with lentivirus vector containing an EF promoter derived-EGFP expressing cassette, were treated with the CRISPR/Cas9 system. A schematic of the lentivirus vector used in this assay is shown on top. The percentage of GFP positive cells after single or double TF of CRISPR/Cas9 components is shown on the bottom (n = 3). (B) Excision of LTIG provirus with CRISPR/Cas9 system. The genomic DNA was extracted from the samples derived from Fig. 3C and qPCR was performed (n = 3). The relative amount of EGFP DNA is shown. (C) PCR amplification of HIV-1 provirus. A primer set was designed for the host cell genome sequence flanking the proviral integration site in c19. The schematic of PCR products indicating genomic sequences, full-length provirus and one LTR footprint resulting from proviral excision are shown on the right side. (D) DNA sequence of one LTR footprint resulted from proviral excision. TAR sequence of WT LTR is shown on the top in bold. Target sequence of T5 gRNA is indicated in orange. The putative cleavage site is indicated with an arrowhead. LTR sequences from five clones are shown in the middle. Deletions are indicated by dashes. Insertion is shown in Red. The 5-bp direct repeat in host DNA, flanking LTR ends, is shown in green. The host cell genome sequence is indicated on the bottom.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 6 Not checked · 31 Own results and interpretations

23 more claims

Create a free account to see all 48 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 14

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 28 references

Cited by

Items 501–562 of 562

Metadata

Authors
Ebina, H., Misawa, N., Kanemura, Y., & Koyanagi, Y.
Affiliations
Kyoto University (JP)
Corresponding author
Ebina, Hirotaka
Venue
Scientific Reports
Published
2013-08-26
Volume
3
Issue
1
Pages
2510-2510
ISSN
2045-2322 (ISSN-L)
OpenAlex
W1966452674
Cited by
565
References
28
Citations by year
2026: 13 · 2025: 19 · 2024: 39 · 2023: 28 · 2022: 50 · 2021: 52 · 2020: 51 · 2019: 35 · 2018: 46 · 2017: 58 · 2016: 73 · 2015: 61 · 2014: 36 · 2013: 3
FWCI
25.82
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
Funders
  • Ministry of Education, Culture, Sports, Science and Technology (24115008)
  • Japan Society for the Promotion of Science (24790438, 24390112)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
CRISPR/Cas9, HIV-1 provirus, latent HIV-1 reservoir, HIV-1 latency, HIV-1 cure, genome editing, T cells, HIV-1 reactivation
MeSH terms
HeLa Cells, Humans, HIV-1, HIV Long Terminal Repeat, Virus Latency, Gene Silencing, HEK293 Cells, CRISPR-Cas Systems, CRISPR-Associated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.